Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents

Author： Meletiadis Joseph   Chanock Stephen   Walsh Thomas J  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.9, Iss.5, 2008-05, pp. : 561-584

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenetics and pharmacogenomics: adverse drug reactions

By Jorgensen Andrea   Alfirevic Ana  

Pharmacogenomics, Vol. 9, Iss. 10, 2008-10 ,pp. : 1397-1401

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics and adverse drug reactions: the case of statins

By Giorgi Mariano A   Caroli Christian   Arazi Hernáán Cohen   Di Girolamo Guillermo  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1499-1509

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenomics of adverse drug reactions: practical applications and perspectives

By Becquemont Laurent  

Pharmacogenomics, Vol. 10, Iss. 6, 2009-06 ,pp. : 961-969

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics and active surveillance for serious adverse drug reactions in children

By Loo Tenneille T   Ross Colin JD   Sistonen Johanna   Visscher Henk   Madadi Parvaz   Koren Gideon   Hayden Michael R   Carleton Bruce C  

Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. : 1269-1285

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics of severe cutaneous adverse reactions

By Kaniwa Nahoko   Saito Yoshiro  

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 595-598

Future Medicine

Access to resources Recommend Favorite